Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single Arm Multiple Dose Study to Assess the Efficacy and Safety of ANB019 in Subjects With Generalized Pustular Psoriasis

NCT03619902 is registered in ClinicalTrials.gov with Vanda Pharmaceuticals as lead sponsor.

NCT NCT03619902
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03619902 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single Arm Multiple Dose Study to Assess the Efficacy and Safety of ANB019 in Subjects With Generalized Pustular Psoriasis
Lead sponsor
Vanda Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
January 30, 2019
Completion date
January 20, 2021
Enrollment
8 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

generalized pustular psoriasis